Abacus Medicine supplies original prescription medicine in Europe through parallel import. In 2017 revenues grew 42% compared to 2016's 59%. The company is now looking to tap into the markets for unregistered drugs and the supply of pharmaceuticals for clinical trials, which are two markets with a total global value of more than DKK 50b. In order to do this, the company needs to raise funds and are highly considering an IPO in the near future according to Borsen.
